Total views : 67

A Review on Drug Interactions in Oral Hypoglycemic Drugs by Mechanism of Cytochrome P450 Enzyme Inhibition

Affiliations

  • Krupanidhi College of Pharmacy, #12/1, Chikkabellandur, Carmelaram Post, Varthur Hobli , Bangalore - 560035, KA, India

Abstract


Purpose: Drug interaction is a phenomenon that has to be thoroughly investigated in order to avoid adverse effects. This review article highlights the drug interaction of oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition.

Approach: Published articles from PubMed and other sources were used to review and compile these drug interaction studies.

Findings: Drug interaction in oral hypoglycemics by mechanism of cytochrome P450 enzyme inhibition can increase the risk of hypoglycemia in diabetic patients and hence dose adjustments may be required.

Conclusion: These drug interaction studies are essential for patients suffering from diabetes mellitus as it prevents the risk of occurrence of hypoglycemia. This information is also important for the prescribing physicians as dose alteration or alternate drugs need to administered in case of concomitant administration of drugs in case of polypharmacy.


Keywords

Drug Interaction, CYP450 Enzyme, Oral Hypoglycemics, Food-Drug Interaction.

Full Text:

 |  (PDF views: 46)

References


  • Mallet L, hypoglycemia A, Huang A. The challenge of managing drug interactions in elderly people. The Lancet. 2007 Jul 20;370(9582):185-91.
  • lberti KG, Zimmet PF. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic medicine. 1998 Jul 1;15(7):539-53.
  • Peart GF, Boutagy J, Shenfield GM. The metabolism of glyburide in subjects of known debrisoquin phenotype. Clinical Pharmacology & Therapeutics. 1989 Mar 1;45(3):277-84.
  • Jönsson A, Karlsson MO, Melander A. Concentration‐effect relations of glibenclamide and its active metabolites in man: modelling of Pharmacokinetics and Pharmacodynamics. British journal of clinical pharmacology. 1997 Apr 1;43(4):373-81.
  • Wensing G. Topics in clinical pharmacology: Glipizide: an oral hypoglycemic drug. The American journal of the medical sciences. 1989 Jul 1;298(1):69-71.
  • Brian WR. Hypoglycemic agents, In: Levy RH, Thummel KE, Tranger WF, Haunsten PD, Eichelbaum M, eds. Metabolic drug interactions. Philadelphia: Lippincott Williams & Wilkins; 2000. 429-43.
  • Kidd RS, Straughn AB, Meyer MC, Blaisdell J, Goldstein JA, Dalton JT. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9* 3 allele. Pharmacogenetics and Genomics. 1999 Feb 1;9(1):71-80.
  • Lamy PP. Classification of drug interactions. Drug Information Journal. 1972 Jan;6(1):99-107.
  • Prescott LF. Drug interaction during absorption. Naunyn-Schmiedeberg's archives of pharmacology. 1977 Jan 1;297(1):S29-31.
  • Shitara Y, Horie T, Sugiyama Y. Transporters as a determinant of drug clearance and tissue distribution. European journal of pharmaceutical sciences. 2006 Apr 30;27(5):425-46.
  • Lu Z, Zhang R, Diasio RB. Population characteristics of hepatic dihydropyrimidine dehydrogenase activity, a key metabolic enzyme in 5‐fluorouracil chemotherapy. Clinical Pharmacology & Therapeutics. 1995 Nov 1;58(5):512-22.
  • Marchitti SA, Brocker C, Stagos D, Vasiliou V. Non-P450 aldehyde oxidizing enzymes: the aldehyde dehydrogenase superfamily. Expert opinion on drug metabolism & toxicology. 2008 Jun 1;4(6):697-720.
  • Wormhoudt LW, Commandeur JN, Vermeulen NP. Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Critical reviews in toxicology. 1999 Jan 1;29(1):59-124.
  • Willey JC, Coy E, Brolly C, Utell MJ, Frampton MW, Hammersley J, Thilly WG, Olson D, Cairns K. Xenobiotic metabolism enzyme gene expression in human bronchial epithelial and alveolar macrophage cells. American journal of respiratory cell and molecular biology. 1996 Mar;14(3):262-71.
  • Tom Lynch, Amy Price. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:3916.
  • Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol.. 2005 Feb 10;45:689-723.
  • Krentz AJ, Bailey CJ. Oral antidiabetic agents. Drugs. 2005 Feb 1;65(3):385-411.
  • Groop LC. Sulfonylureas in NIDDM. Diabetes care. 1992 Jun 1;15(6):737-54.
  • Dornhorst A. Insulinotropic meglitinide analogues. The Lancet. 2001 Nov 17;358(9294):1709-16.
  • Goldstein BJ. Current views on the mechanism of action of thiazolidinedione insulin sensitizers. Diabetes technology & therapeutics. 1999 Sep 1;1(3):267-75.
  • Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinology and metabolism clinics of North America. 1997 Sep 1;26(3):539-51.
  • Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidylpeptidase4 (DPP-4). Best Practice & Research Clinical Endocrinology & Metabolism. 2009 Aug 31;23(4):479-86.
  • Neumiller JJ. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Journal of the American Pharmacists Association: JAPhA. 2008 Dec;49:S16-29.
  • Reda TK, Geliebter A, Pi‐Sunyer FX. Amylin, food intake, and obesity. Obesity research. 2002 Oct 1;10(10):1087-91.
  • Neumiller JJ, White JR, Campbell RK. Sodium-glucose co-transport inhibitors. Drugs. 2010 Mar 1;70(4):377-85.
  • Hansen JM, Christensen LK. Drug interactions with oral sulphonylurea hypoglycaemic drugs. Drugs. 1977 Jan 1;13(1):24-34.
  • Kirchheiner J, Roots I, Goldammer M, Rosenkranz B, Brockmöller J. Effect of genetic polymorphisms in cytochrome P450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs. Clinical pharmacokinetics. 2005 Dec 1;44(12):1209-25.
  • Li XQ, Andersson TB, Ahlström M, Weidolf L. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug metabolism and disposition. 2004 Aug 1;32(8):821-7.
  • Rajendra SV, Narsu L, Ramachandra Setty S. Influence of rabeprazole on antidiabetic effect of sulfonylureas in diabetic rats. Pharmacologyonline. 2008;3:1017-23.
  • Hatanaka T. Clinical pharmacokinetics of pravastatin. Clinical pharmacokinetics. 2000 Dec 1;39(6):397-412.
  • Jacobsen W, Kirchner G, Hallensleben K, Mancinelli L, Deters M, Hackbarth I, Benet LZ, Sewing KF, Christians U. Comparison of cytochrome P-450dependent metabolism and drug interactions of the 3-hydroxy-3methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver. Drug metabolism and disposition. 1999 Feb 1;27(2):173-9.
  • Transon C, Leemann T, Dayer P. In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors. European journal of clinical pharmacology. 1996 May 1;50(3):209-15.
  • Satyanarayana S, Chandrasekhar MS, Palakshi Gouda O, Eswar Kumar K. Drug-drug interaction between Pravastatin and Gliclazide in animal models. Scholarly Research Exchange. 2008 Sep 3;2008.
  • Sahi J, Black CB, Hamilton GA, Zheng X, Jolley S, Rose KA, Gilbert D, LeCluyse EL, Sinz MW. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Drug Metabolism and Disposition. 2003 Apr 1;31(4):439-46.
  • Chaitanya Gadiko , Prakash Pamu, Eswar Kumar Kilari. Effect of amiodarone on the pharmacodynamics of gliclazide in animal models. International Journal of Pharmacy and Pharmaceutical Sciences. 2013;5(4):290-93.
  • Mastan SK, Kumar KE. Influence of atazanavir on the pharmacodynamics and pharmacokinetics of gliclazide in animal models. International Journal of Diabetes Mellitus. 2010 Apr 30;2(1):56-60.
  • Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. Journal of Pharmacology and Experimental Therapeutics. 1996 Apr 1;277(1):423-31.
  • Mastan SK, Kumar KE. Influence of non-nucleoside reverse transcriptase inhibitors (efavirenz and nevirapine) on the pharmacodynamic activity of gliclazide in animal models. Diabetology & metabolic syndrome. 2009 Oct 9;1(1):15.
  • Mouly S, Lown KS, Kornhauser D, Joseph JL, Fiske WD, Benedek IH, Watkins PB. Hepatic but not intestinal CYP3A4 displays dose‐dependent induction by efavirenz in humans. Clinical Pharmacology & Therapeutics. 2002 Jul 1;72(1):1-9.
  • Mastan S, Eswar Kumar K. Effect of ritonavir on the pharmacodynamics of gliclazide in animal models. Diabetologia Croatica. 2009;38(4):105-3.
  • Brian WR, Srivastava PK, Umbenhauer DR, Lloyd RS, Guengerich FP. Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry. 1989 Jun;28(12):4993-9.
  • Back DJ, Tjia JF, Karbwang J, Colbert J. In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. British journal of clinical pharmacology. 1988 Jul 1;26(1):23-9.
  • Sugita OS, Sawada YA, Sugiyama Y, Iga TA, Hanano MA. Kinetic analysis of tolbutamide-sulfonamide interaction in rabbits based on clearance concept. Prediction of species difference from in vitro plasma protein binding and metabolism. Drug metabolism and disposition. 1984 Jan 1;12(1):131-8.
  • Sugita O, Sawada Y, Sugiyama Y, Iga T, Hanano M. Effect of sulfaphenazole on tolbutamide distribution in rabbits: Analysis of interspecies differences in tissue distribution of tolbutamide. Journal of pharmaceutical sciences. 1984 May 1;73(5):631-4.
  • Komatsu K, Ito K, Nakajima Y, Kanamitsu SI, Imaoka S, Funae Y, Green CE, Tyson CA, Shimada N, Sugiyama Y. Prediction of in vivo drug-drug interactions between tolbutamide and various sulfonamides in humans based on in vitro experiments. Drug Metabolism and Disposition. 2000 Apr 1;28(4):475-81.
  • Hidaka M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Arimori K. Potent inhibition by star fruit of human cytochrome P450 3A (CYP3A) activity. Drug metabolism and disposition. 2004 Jun 1;32(6):581-3.
  • Hidaka M, Okumura M, Fujita KI, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug metabolism and disposition. 2005 May 1;33(5):644-8.
  • Fujita KI, Hidaka M, Takamura N, Yamasaki K, Iwakiri T, Okumura M, Kodama H, Yamaguchi M, Ikenoue T, Arimori K. Inhibitory effects of citrus fruits on cytochrome P450 3A (CYP3A) activity in humans. Biological and Pharmaceutical Bulletin. 2003;26(9):1371-3.
  • Hidaka M, Nagata M, Kawano Y, Sekiya H, Kai H, Yamasaki K, Okumura M, Arimori K. Inhibitory effects of fruit juices on cytochrome P450 2C9 activity in vitro. Bioscience, biotechnology, and biochemistry. 2008 Feb 23;72(2):40611.
  • Nagata M, Hidaka M, Sekiya H, Kawano Y, Yamasaki K, Okumura M, Arimori K. Effects of pomegranate juice on human cytochrome P450 2C9 and tolbutamide pharmacokinetics in rats. Drug metabolism and disposition. 2007 Feb 1;35(2):302-5.
  • Bailey DG, Dresser GK. Interactions between grapefruit juice and cardiovascular drugs. American Journal of Cardiovascular Drugs. 2004 Sep 1;4(5):281-97.